Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$0.29.

  • Myriad Genetics' EPS (Basic) fell 2083.33% to -$0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.33, marking a year-over-year decrease of 23828.12%. This contributed to the annual value of -$1.41 for FY2024, which is 5581.52% up from last year.
  • As of Q3 2025, Myriad Genetics' EPS (Basic) stood at -$0.29, which was down 2083.33% from -$3.57 recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' EPS (Basic) registered a high of $0.31 during Q3 2021, and its lowest value of -$3.57 during Q2 2025.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.34 (2023), whereas its average is -$0.54.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 25500.0% in 2021, then crashed by 77073.17% in 2025.
  • Myriad Genetics' EPS (Basic) (Quarter) stood at -$0.1 in 2021, then plummeted by 420.0% to -$0.52 in 2022, then surged by 34.62% to -$0.34 in 2023, then plummeted by 37.97% to -$0.47 in 2024, then surged by 38.18% to -$0.29 in 2025.
  • Its EPS (Basic) was -$0.29 in Q3 2025, compared to -$3.57 in Q2 2025 and -$0.0 in Q1 2025.